Heparin (As Sodium)
- Heparin (As Sodium)
- No Brand Name
- Solution and Powder for Injection
- 5000 IU/mL
- Ampoule
- 1mL
-
• DVT & PE
• Acute Coronary Syndromes
• Anticoagulation
• Catheter Patency
• Acute Coronary Syndromes
• Anticoagulation
• Catheter Patency
Mechanism of Action
Mechanism for low dose: Inactivates factor Xa and inhibits conversion of prothrombin to thrombin
Mechanism for high dose: Inactivates factors IX, X, XI, and XII and thrombin and inhibits conversion of fibrinogen to fibrin
Also inhibits activation of factor VIII
Pharmacokinetics
Bioavailability: 22-40%
Onset: IV (immediate), SC (20-30 min)
Excretion: Urine
Contraindications
• History of Pentosan Polysulfate-induced thrombocytopenia (HIT) (with or without thrombosis)
• Uncontrollable active bleeding state except when this is due to disseminated intravascular coagulation (DIC)
• In whom suitable blood coagulation tests – eg, whole blood clotting time, partial thromboplastin time, etc, – cannot be performed at appropriate intervals (contraindication refers to full-dose heparin, there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin)
• Cases where the administration of sodium or chloride could be clinically detrimental (large volume heparin 2 unit/mL IV solutions only)
• Known hypersensitivity to heparin
Adverse Reactions
Heparin-induced thrombocytopenia, possibly delayed
Major Drug Interactions
Corticorelin - Defibrotide - Mifepristone - Prothrombin complex concentrate, human
Warnings
• Monitor therapy with aPTT
• Heparin may prolong PT
Recommendations for Patient
-
Pregnancy Considerations
There are no available data on heparin sodium injection use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage.
Breastfeeding Considerations
There is no information regarding presence of heparin sodium injection in human milk, effects on breastfed infant, or on milk production.
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Mechanism for low dose: Inactivates factor Xa and inhibits conversion of prothrombin to thrombin
Mechanism for high dose: Inactivates factors IX, X, XI, and XII and thrombin and inhibits conversion of fibrinogen to fibrin
Also inhibits activation of factor VIII
Pharmacokinetics
Bioavailability: 22-40%
Onset: IV (immediate), SC (20-30 min)
Excretion: Urine
Contraindications
• History of Pentosan Polysulfate-induced thrombocytopenia (HIT) (with or without thrombosis)
• Uncontrollable active bleeding state except when this is due to disseminated intravascular coagulation (DIC)
• In whom suitable blood coagulation tests – eg, whole blood clotting time, partial thromboplastin time, etc, – cannot be performed at appropriate intervals (contraindication refers to full-dose heparin, there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin)
• Cases where the administration of sodium or chloride could be clinically detrimental (large volume heparin 2 unit/mL IV solutions only)
• Known hypersensitivity to heparin
Adverse Reactions
Heparin-induced thrombocytopenia, possibly delayed
Major Drug Interactions
Corticorelin - Defibrotide - Mifepristone - Prothrombin complex concentrate, human
Warnings
• Monitor therapy with aPTT
• Heparin may prolong PT
Recommendations for Patient
-
Pregnancy Considerations
There are no available data on heparin sodium injection use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage.
Breastfeeding Considerations
There is no information regarding presence of heparin sodium injection in human milk, effects on breastfed infant, or on milk production.
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Send to other people